(-)-Sotalol | CAS#30236-31-8 | beta-adrenergic receptor blocker

MedKoo Cat#: 597937 | Name: (-)-Sotalol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(-)-Sotalol is a non-selective competitive beta-adrenergic receptor blocker that also exhibits Class III antiarrhythmic properties.

Chemical Structure

(-)-Sotalol

CAS#30236-31-8

Theoretical Analysis

MedKoo Cat#: 597937

Name: (-)-Sotalol

CAS#: 30236-31-8

Chemical Formula: C12H20N2O3S

Exact Mass: 272.1195

Molecular Weight: 272.36

Elemental Analysis: C, 52.92; H, 7.40; N, 10.29; O, 17.62; S, 11.77

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

(-)-Sotalol; (R)-Sotalol; D-Sotalol; l-Sotalol;

IUPAC/Chemical Name

(R)-N-(4-(1-hydroxy-2-(isopropylamino)ethyl)phenyl)methanesulfonamide

InChi Key

ZBMZVLHSJCTVON-LBPRGKRZSA-N

InChi Code

InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3/t12-/m0/s1

SMILES Code

CS(=O)(NC1=CC=C([C@@H](O)CNC(C)C)C=C1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 272.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Darpo B, Karnad DR, Badilini F, Florian J, Garnett CE, Kothari S, Panicker GK, Sarapa N. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol. 2014 Mar;77(3):522-31. doi: 10.1111/bcp.12201. PubMed PMID: 23819796; PubMed Central PMCID: PMC4371537. 2: Feiner M, Laforsch C, Letzel T, Geist J. Sublethal effects of the beta-blocker sotalol at environmentally relevant concentrations on the New Zealand mudsnail Potamopyrgus antipodarum. Environ Toxicol Chem. 2014 Nov;33(11):2510-5. doi: 10.1002/etc.2699. Epub 2014 Aug 28. PubMed PMID: 25132045. 3: Rivolta MW, Mainardi LT, Sassi R. Quantification of ventricular repolarization heterogeneity during moxifloxacin or sotalol administration using [Formula: see text]-index. Physiol Meas. 2015 Apr;36(4):803-11. doi: 10.1088/0967-3334/36/4/803. Epub 2015 Mar 23. PubMed PMID: 25798997. 4: Somberg JC, Preston RA, Ranade V, Cvetanovic I, Molnar J. Gender differences in cardiac repolarization following intravenous sotalol administration. J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):86-92. doi: 10.1177/1074248411406505. Epub 2011 Apr 28. PubMed PMID: 21527783. 5: Tesic D, Kostic M, Paunovic D, Jankovic SM. Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia. Kardiol Pol. 2015;73(4):287-95. doi: 10.5603/KP.a2014.0228. Epub 2014 Nov 27. PubMed PMID: 25428811. 6: Johnson SM, Brophy JM. Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation. Int J Cardiol. 2016 Jul 1;214:502-7. doi: 10.1016/j.ijcard.2016.04.032. Epub 2016 Apr 9. PubMed PMID: 27107151. 7: Finks SW, Rogers KC, Manguso AH. Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement. Int J Pharm Pract. 2011 Aug;19(4):281-6. doi: 10.1111/j.2042-7174.2011.00094.x. Epub 2011 Mar 15. PubMed PMID: 21733016. 8: Ensafi AA, Allafchian AR, Rezaei B, Mohammadzadeh R. Characterization of carbon nanotubes decorated with NiFe2O4 magnetic nanoparticles as a novel electrochemical sensor: application for highly selective determination of sotalol using voltammetry. Mater Sci Eng C Mater Biol Appl. 2013 Jan 1;33(1):202-8. doi: 10.1016/j.msec.2012.08.031. Epub 2012 Aug 21. PubMed PMID: 25428063. 9: Derakhchan K, Chui RW, Stevens D, Gu W, Vargas HM. Detection of QTc interval prolongation using jacket telemetry in conscious non-human primates: comparison with implanted telemetry. Br J Pharmacol. 2014 Jan;171(2):509-22. doi: 10.1111/bph.12484. PubMed PMID: 24372552; PubMed Central PMCID: PMC3904268. 10: Leslie SD. Sotalol-associated cardiogenic shock in a patient with asymptomatic transient rate-related cardiomyopathy. Med J Aust. 2013 Nov 18;199(10):658-9. PubMed PMID: 24237089. 11: Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005 May 5;352(18):1861-72. PubMed PMID: 15872201. 12: Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011 Mar;13(3):329-45. doi: 10.1093/europace/euq450. Epub 2011 Jan 11. PubMed PMID: 21227948. 13: Gelzer AR, Kraus MS, Rishniw M, Hemsley SA, Moïse NS. Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study. J Vet Cardiol. 2010 Aug;12(2):93-106. doi: 10.1016/j.jvc.2010.06.001. PubMed PMID: 20663731. 14: Ruffy R. Sotalol. J Cardiovasc Electrophysiol. 1993 Feb;4(1):81-98. Review. PubMed PMID: 8287239. 15: Hohnloser SH, Woosley RL. Sotalol. N Engl J Med. 1994 Jul 7;331(1):31-8. Review. PubMed PMID: 8202100. 16: Kim MH, Smith PJ, Jhaveri M, Lin J, Klingman D. One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis. Clin Ther. 2011 Nov;33(11):1668-1681.e1. doi: 10.1016/j.clinthera.2011.10.005. PubMed PMID: 22108302. 17: Borisova EV, Afanasyev SA, Rebrova TY, Kisteneva IV, Batalov RE, Popov SV. [A change in adrenal responsiveness in sotalol-treated patients with paroxysmal atrial fibrillation depending on autonomic nervous system tone]. Ter Arkh. 2016;88(1):35-39. doi: 10.17116/terarkh201688135-39. Russian. PubMed PMID: 26978607. 18: Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006 Jan 11;295(2):165-71. PubMed PMID: 16403928. 19: Guerra F, Hohnloser SH, Kowey PR, Crijns HJ, Aliot EM, Radzik D, Roy D, Connolly S, Capucci A. Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. Clin Cardiol. 2014 Dec;37(12):717-24. doi: 10.1002/clc.22342. Epub 2014 Dec 2. PubMed PMID: 25470298. 20: Broux B, De Clercq D, Decloedt A, De Baere S, Devreese M, Van Der Vekens N, Ven S, Croubels S, van Loon G. Pharmacokinetics of intravenously and orally administered sotalol hydrochloride in horses and effects on surface electrocardiogram and left ventricular systolic function. Vet J. 2016 Feb;208:60-4. doi: 10.1016/j.tvjl.2015.09.021. Epub 2015 Oct 1. PubMed PMID: 26670333.